Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
REGN846 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Dose 1 | EXPERIMENTAL | (3:1, active: placebo) |
| Dose 2 | EXPERIMENTAL | (3:1, active: placebo) |
| Dose 3 | EXPERIMENTAL | (3:1, active: placebo) |
| Dose 4 | EXPERIMENTAL | (3:1, active: placebo) |
| Dose 5 | EXPERIMENTAL | (3:1, active: placebo) |
| Name | Type | Description |
|---|---|---|
| REGN846 | BIOLOGICAL | 5 IV cohorts (Dose 1, 2, 3, 4, 5) |
Inclusion Criteria: * Healthy men and women between the ages of 18 and 65; women must be postmenopausal or surgically sterile * Body Mass Index (BMI) between 18.0 and 30.0 kg/m2, inclusive * Normal vital signs after resting in a sitting position for 5 minutes: * Normal standard 12-lead ECG * Willin...
REGN846 is an investigational monoclonal antibody developed by Regeneron Pharmaceuticals, Inc. It has been studied in a Phase 1 clinical trial in healthy adult volunteers. REGN846 is not approved for any indication and remains in early clinical development.
REGN846 is developed by Regeneron Pharmaceuticals, Inc., which trades on Nasdaq under the ticker REGN. The company sponsored the Phase 1 study of REGN846 conducted in Australia.
REGN846 is in Phase 1 development. One Phase 1 trial has been completed, and no active trials are currently listed. The program has not advanced beyond early-stage clinical testing, and REGN846 is not approved for any use.
REGN846 has been evaluated in one Phase 1 trial, NCT01209793, titled a safety and tolerability study in healthy volunteers. The trial enrolled 40 participants, was randomized, double-blind, and controlled, and was conducted in Australia. It is listed as completed.
Yes, SAR302352 is an alternative designation used for REGN846. The Phase 1 trial NCT01209793 refers to the drug as REGN846 (SAR302352), so both names identify the same monoclonal antibody candidate.
The REGN846 Phase 1 trial, NCT01209793, was a randomized, double-blind, controlled study of safety and tolerability in healthy volunteers. It enrolled 40 participants aged 18 years and older of all sexes in Australia. The study is complete.